Literature DB >> 7308268

Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis.

P Schmidt, D Loew, J Dycka, H Kopsa, P Balcke, J Zazgornik, E Deutsch.   

Abstract

The pharmacodynamic effects of muzolimine and furosemide were compared in a single dose cross-over study in 8 patients on regular dialysis treatment, who had a residual diuresis of more than 300 ml/day. The study periods comprised two dialysis-free intervals of 3 days. On the second dialysis-free day either muzolimine 240 mg or furosemide 240 mg was administered orally. Urine was collected in 12-h periods on the pre-treatment, treatment and post-treatment days, and the excretion of sodium, potassium, urea and creatinine were measured. After administration of muzolimine 240 mg urine volume rose to twice that of the previous day, and sodium excretion increased approximately threefold. In contrast, the effect of furosemide 240 mg was not a pronounced; the diuresis was only 1.6 times that on the previous day and natriuresis was only 2.2 times as large. Excretion of potassium and creatinine was only slightly increased by either substance. The elimination of urea was increased by both substances to the same degree as the corresponding increase in diuresis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308268     DOI: 10.1007/bf00554662

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  3-Amino-1-(3,4-dichloro-alpha-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821), a potent diuretic from a new substance class.

Authors:  E Möller; H Horstmann; K Meng; D Loew
Journal:  Experientia       Date:  1977-03-15

2.  [Possibilities and limitations of high dosage diuretic therapy in hydropic renal insufficiency].

Authors:  A Heidland; K Klütsch; A Moormann; H Hennemann
Journal:  Dtsch Med Wochenschr       Date:  1969-08-01       Impact factor: 0.628

3.  Diuretic action of Bay g 2821 in oedema-free volunteers.

Authors:  D Loew
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

4.  Diuretic effects of Bay g 2821 in patients with advanced renal failure.

Authors:  A Röckel
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

5.  Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency.

Authors:  P Schmidt; D Loew; J Dýcka; H Kopsa; P Balcke; J Zazgornik; E Deutsch
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine).

Authors:  D Loew; W Ritter; J Dycka
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

  6 in total
  4 in total

1.  Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis.

Authors:  Helton P Lemes; Salustiano Araujo; Daniella Nascimento; Danny Cunha; Cesar Garcia; Vinicius Queiroz; Sebastião R Ferreira-Filho
Journal:  Clin Exp Nephrol       Date:  2011-03-18       Impact factor: 2.801

Review 2.  The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide.

Authors:  T Risler; B Krämer; G A Müller
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency.

Authors:  R W van Olden; J J van Meyel; P G Gerlag
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease.

Authors:  Chakradhari Inampudi; Paulino Alvarez; Rabea Asleh; Alexandros Briasoulis
Journal:  Curr Cardiol Rev       Date:  2018-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.